HiFiBiO Therapeutics announced a partnership with Pharmsynthez PJSC, and Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry RAS (IBCh). The partnership aims to advance HFB30132A, a SARS-CoV-2 neutralizing antibody for the treatment of COVID-19, through clinical development and commercial sale in Russia, pending approval from the Ministry of Health of the Russian Federation. An IND has been submitted to the Ministry of Health and clinical sites have been selected for a Phase I/II study. Per the agreement, Pharmsynthez will purchase HFB30132A for clinical trials in Russia. Upon regulatory approval, Pharmsynthez will continue to commercialize the product as the exclusive partner of HiFiBiO Therapeutics in Russia. HiFiBiO Therapeutics retains all rights and continues to develop and commercialize HFB30132A globally. HiFiBiO has leveraged its expertise in immune modulation and single-cell science to rapidly discover, engineer, and develop HFB30132A in less than six months. Additionally, the company is currently dosing the second cohort of healthy volunteers in a Phase I ascending dose study (NCT04590430) to assess the safety, tolerability and pharmacokinetics of HFB30132A. This Phase I study will be followed by global phase II/III clinical trials in high-risk adults with asymptomatic or mild to moderate COVID-19.